We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Multiplex Molecular Assays for Respiratory Viruses Evaluated

By LabMedica International staff writers
Posted on 02 May 2017
Acute respiratory infections (ARI) are one of the major causes of mortality worldwide, and approximately half are caused by respiratory viruses (RV). More...
There are several types of tests for detection of these viruses.

The nucleic acid amplification test (NAAT) has widely been accepted in recent years and has advantages in comparison to the classical methods of viral culture and direct fluorescent antibody tests. NAAT has superior sensitivity identifying RV cases not detected by classical methods and RV testing results are available faster than those of viral cultures.

Laboratory scientists at Kangwon National University School of Medicine collected between December 2015 and March 2016, 201 respiratory samples (161 nasopharyngeal swab samples and 40 sputum samples) from young male soldiers (age range 18-27 years, median 21 years) with acute respiratory illness. Nasopharyngeal swab samples were obtained using flocked swabs and sputum samples were received in sterile plastic containers.

A nucleic acid extraction system was used for each RV assay. The team tested the samples with three commercial RV assays: Seegene Anyplex II RV16, LG AdvanSure RV, and Biosewoom Real-Q RV. The additional tests for the discrepant results were conducted by repeat RV assay or monoplex PCR coupled direct sequencing. The AD assay performs both reverse-transcription (RT) reaction with the extracted RNA from specimen and multiplex PCR reaction simultaneously and conducted in a SLAN Real-time PCR detection system.

The scientists found that of the 201 samples, AP, AD, and RQ detected 105 (52.2%), 99 (49.3%), and 95 (47.3%) positive cases respectively. Viral co-infection samples were identified in AP assay for 24 (11.9%) patients, in AD assay for 17 (8.5%) patients, and in RQ assay for 11 (5.5%) patients. The performance of the three assays was very similar, with 94%-100% agreement for all comparisons of each virus types. The additional testing of samples showed discrepant results demonstrating that AD assay had the highest rate of concordance with original results.

The authors concluded that the agreement of the three assays were very good, with 94%-100% agreement for all comparisons. They suggest that all multiplex assay would be suitable for the detection of for respiratory viruses in clinical setting. The study was published on April 11, 2017, in the Journal of Clinical Laboratory Analysis.


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.